A new editorial paper titled "The double-edge sword of CRISPR application for in vivo studies" has been published inOncotarget. In this new paper, researcher Martin K. Thomsen from Aarhus University ...
Vertex and CRISPR Therapeutics have taken a small step toward a landmark approval, securing European Medicines Agency (EMA) validation of the approval application for their CRISPR-Cas9 candidate. The ...
Are there significant gains ahead for one (or both) of these innovative biotechs?
This article was written for our sponsor, Innovation Road Trip. Eradication of certain diseases, increasing crop sizes, reducing pest populations — the current and future applications of CRISPR have ...
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...
CRISPR gene editing machinery holds the potential to transform the treatment of numerous diseases, but it requires effective delivery systems to get into tissues and ...
On October 22, Nobel Prize–winning biochemist Dr. Jennifer Doudna dined with supporters of UCSB Arts & Lectures (A&L) and the Cancer Foundation of S.B. (CFSB). The intimate, al fresco dinner party at ...
The Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA is meeting tomorrow, Tuesday, October 31, 2023, to review a Biologics License Application by Vertex Pharmaceuticals Inc. for ...
BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on November 27, 2023, entitled, “The double-edge sword of CRISPR application for in vivo studies.” In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results